A multi-part processed human amniotic composition configured to treat Peyronie's disease in a subject in need thereof by intracorporeal injection of the composition into the corpus cavernosum of the subject to reduce plaque size associated with Peyronie's disease. The multi-part processed human amniotic composition includes a micronized human amnion composition; and an aqueous human amniotic fluid filtrate configured to reconstitute and suspend the micronized human amnion composition therein. In certain aspects, the multi-part processed human amniotic compositions are not processed with exogenous enzymes during production thereof and do not include exogenous enzymes, such as collagenase, added thereto.
MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN
A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A processed human umbilical cord composition for the treatment of Peyronie's disease by intracorporeal injection in a subject in need thereof with an effective amount of the composition. The composition including an aqueous human umbilical cord filtrate having endogenous hyaluronic acid (HA) and/or hyaluronan, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycans (sGAGs), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, tissue inhibitor of metalloproteinase 1 (TIMP-1), aggrecan, or a combination thereof therein at effective amount to reduce size of a Peyronie's disease plaque.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
9.
HUMAN UMBILICAL COMPOSITIONS AND METHODS FOR DERMAL APPLICATION
An aqueous, non-immunogenic, composition derived from human umbilical cords and methods of making thereof are described. The non-immunogenic composition for topical, subcutaneous, or intradermal use in a human subject in need thereof. The non-immunogenic composition may include an aqueous human umbilical cord filtrate prepared without the use of exogenous enzymes resulting in exogenous enzymatic degradation/digestion.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
An aqueous, non-immunogenic, composition derived from human umbilical cords and methods of making thereof are described. The non-immunogenic composition for topical, subcutaneous, or intradermal use in a human subject in need thereof. The non-immunogenic composition may include an aqueous human umbilical cord filtrate prepared without the use of exogenous enzymes resulting in exogenous enzymatic degradation/digestion.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
human allograft tissue
16.
Micronized compositions for wound healing prepared from intact human amnion-chorion tissue having an intact intermediate spongy layer positioned there between
A sterile micronized composition prepared from intact human placental tissue for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A processed human umbilical cord composition for the treatment of Peyronie's disease by intracorporeal injection in a subject in need thereof with an effective amount of the composition. The composition including an aqueous human umbilical cord filtrate having endogenous hyaluronic acid (HA) and/or hyaluronan, fibronectin, insulin growth factor binding protein- 1 (IGFBP-1 ), sulfated glycosaminoglycans (sGAGs), exosomes, interleukin-1 receptor antagonist (IL-1 ra), hepatocyte growth factor (HGF), transthyretin, tissue inhibitor of metalloproteinase 1 (TIMP-1), aggrecan, or a combination thereof therein at effective amount to reduce size of a Peyronie's disease plaque.
A processed human umbilical cord composition for the treatment of Peyronie's disease by intracorporeal injection in a subject in need thereof with an effective amount of the composition. The composition including an aqueous human umbilical cord filtrate having endogenous hyaluronic acid (HA) and/or hyaluronan, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycans (sGAGs), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, tissue inhibitor of metalloproteinase 1 (TIMP-1), aggrecan, or a combination thereof therein at effective amount to reduce size of a Peyronie's disease plaque.
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
20.
TWO-PART CLOTTING COMPOSITION AND METHODS OF MAKING AND USING THEREOF
A non-immunogenic two-part clotting composition derived from human umbilical cords and methods of making thereof. The non-immunogenic two-part clotting composition may be used for dental purposes (periodontic and/or endodontic purposes) such as packing a subject's gum post-tooth extraction and/or for other wound packing purposes.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
21.
HUMAN UMBILICAL CORD COMPOSITIONS AND METHODS FOR INTRA-ARTICULAR THERAPY
An aqueous, non-immunogenic, injectable composition derived from human umbilical cords and methods of making thereof are described. The non-immunogenic composition is used for articular therapy in a human subject in need thereof. The non-immunogenic composition may include an aqueous human umbilical cord filtrate prepared without the use of exogenous enzymes resulting in exogenous enzymatic degradation/ digestion.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61Q 19/00 - Préparations pour les soins de la peau
23.
STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood. blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
24.
MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN
A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
25.
STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
26.
MULTI-PART PROCESSED HUMAN AMNIOTIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF FOR TREATMENT OF PEYRONIE'S DISEASE
A multi-part processed human amniotic composition configured to treat Peyronie's disease in a subject in need thereof by intracorporeal injection of the composition into the corpus cavernosum of the subject to reduce plaque size associated with Peyronie's disease. The multi-part processed human amniotic composition includes a micronized human amnion composition; and an aqueous human amniotic fluid, filtrate configured to reconstitute and suspend the micronized human amnion composition therein. In certain aspects, the multi-part processed human amniotic compositions are not processed with exogenous enzymes during production thereof and do not include exogenous enzymes, such as collagenase, added thereto.
A non-immunogenic two-part clotting composition derived from human umbilical cords and methods of making thereof. The non-immunogenic two-part clotting composition may be used for dental purposes (periodontic and/or endodontic purposes) such as packing a subject's gum post-tooth extraction and/or for other wound packing purposes.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A non-immunogenic two-part clotting composition derived from human umbilical cords and methods of making thereof. The two-part clotting composition may comprise (a) a micronized human umbilical cord composition; and (b) an aqueous human umbilical cord filtrate configured to reconstitute the micronized human umbilical cord composition. The non-immunogenic two-part clotting composition may be used for dental purposes (periodontic and/or endodontic purposes) such as packing a subject's gum post-tooth extraction and/or for other wound packing purposes.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
Compositions for promoting skin regeneration, skin rejuvenation, and wound healing that include tissues derived from the human placenta, such as the amniotic membrane, chorionic membrane, and umbilical cord. The placental tissues can be combined or compounded with aloe or allantoin or both to form topical treatment creams. Additionally, these compositions have therapeutic and cosmetic uses.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Biological perinatal tissue intended for subsequent implantation Providing consultancy, advice, and information services about the development, implementation, and benefits of cellular therapy services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Acellular amniotic fluid and acellular placental tissue intended for subsequent implantation Providing consultancy, advice, and information services about the development, implementation, and benefits of cellular therapy services
The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
B02C 18/10 - Désagrégation par couteaux ou autres organes coupants ou déchirants qui transforment le matériau en fragmentsHachoirs ou appareils similaires utilisant des vis ou analogue à couteaux rotatifs à l'intérieur de récipients verticaux les organes de transmission étant disposés au-dessus du récipient
B02C 18/30 - Hachoirs à disques perforés et vis d'alimentation
A clip of the present application generally comprises a first clip member, a second clip member, and a retention feature. The first clip member and the second clip member are coupled together and capable of being placed in at least two positions. In the first position, the clip is capable of receiving a bag containing a fluid, and, in the second position, the bag is capable of being held between the first and second clip members. While the clip is holding the bag, two or more pockets are formed in the bag, and the fluid is generally restricted or prohibited from transferring from one pocket to another pocket while the clip is in this position. A retention feature retains the clip, which is holding a bag, to a centrifuge receptacle and allows the clip to be placed in a predetermined position on the centrifuge receptacle.
The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heal seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
B02C 18/10 - Désagrégation par couteaux ou autres organes coupants ou déchirants qui transforment le matériau en fragmentsHachoirs ou appareils similaires utilisant des vis ou analogue à couteaux rotatifs à l'intérieur de récipients verticaux les organes de transmission étant disposés au-dessus du récipient
B02C 18/30 - Hachoirs à disques perforés et vis d'alimentation
The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.
